Dr. Anna Blakney nominated as Tier 2 Canada Research Chair

Dr. Anna Blakney is nominated as a Tier 2 Canada Research Chair in Nucleic Acid Bioengineering. Dr. Blakney’s research program is working at the forefront of RNA technology exploration and application, developing next-generation RNA vaccines and therapies. During her PhD, Dr. Blakney was part of a team that developed a self-amplifying RNA vaccine for COVID-19. Now moving beyond COVID-19 treatment and prevention, Dr. Blakney’s lab is exploring applications for mRNA technology in the treatment of ovarian cancer.